Cartesian Therapeutics (RNAC) Invested Capital (2016 - 2026)
Cartesian Therapeutics (RNAC) has disclosed Invested Capital for 12 consecutive years, with -$148.1 million as the latest value for Q1 2026.
- For Q1 2026, Invested Capital fell 579.78% year-over-year to -$148.1 million; the TTM value through Mar 2026 reached -$148.1 million, down 579.78%, while the annual FY2025 figure was -$126.2 million, 1755.92% down from the prior year.
- Invested Capital hit -$148.1 million in Q1 2026 for Cartesian Therapeutics, down from -$126.2 million in the prior quarter.
- Across five years, Invested Capital topped out at $93.8 million in Q4 2022 and bottomed at -$411.9 million in Q4 2023.
- Average Invested Capital over 5 years is -$24.5 million, with a median of -$2.5 million recorded in 2025.
- Year-over-year, Invested Capital skyrocketed 4910.51% in 2022 and then plummeted 4866.49% in 2025.
- Cartesian Therapeutics' Invested Capital stood at $93.8 million in 2022, then plummeted by 538.97% to -$411.9 million in 2023, then soared by 98.35% to -$6.8 million in 2024, then tumbled by 1755.92% to -$126.2 million in 2025, then decreased by 17.33% to -$148.1 million in 2026.
- According to Business Quant data, Invested Capital over the past three periods came in at -$148.1 million, -$126.2 million, and -$35.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.